deltatrials
Unknown PHASE4 NCT01390961

Comparison of Tolerability Between Two Allergy Drops

Sponsor: Allergan

Conditions Allergic Conjunctivitis
Interventions alacaftadine and naphazoline HCl & pheniramine maleate
Updated 6 times since 2017 Last updated: Jul 7, 2011 Started: Aug 31, 2011 Primary completion: Dec 31, 2011 Completion: Jan 31, 2012

Listed as NCT01390961, this PHASE4 trial focuses on Allergic Conjunctivitis and remains ongoing. Sponsored by Allergan, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE4

  5. Feb 2017 — Jun 2018 [monthly]

    Unknown Status PHASE4

    Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Enrolling By Invitation PHASE4

    First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Allergan
  • Hom, Milton M., OD, FAAO
Data source: Hom, Milton M., OD, FAAO

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Azusa, United States